Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tuberculosis vaccine - Archivel Farma

Drug Profile

Tuberculosis vaccine - Archivel Farma

Alternative Names: RUTI

Latest Information Update: 21 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Archivel Farma
  • Developer Archivel Farma; London School of Hygiene & Tropical Medicine; RUTI Immunotherapeutics
  • Class Antineoplastics; Cancer vaccines; COVID-19 vaccines; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II COVID 2019 infections; Tuberculosis
  • Phase I Allergic rhinitis; Asthma; Bladder cancer

Most Recent Events

  • 10 Feb 2023 Archivel Farma withdrew the phase-II/III MYCOVIND trial in COVID-2019 infections due to decrease of incidence and severity of COVID and availability of therapeutic alternatives (NCT05115019)
  • 22 Dec 2022 Archivel Farma completes a phase II RUTIVAC-1 trial in Tuberculosis (Prevention) in Spain (SC) (NCT03191578)
  • 21 Dec 2022 Tuberculosis vaccine is still in phase I trials for Allergic rhinitis and Asthma (SC, Liposomal) in Spain (Archivel Farma pipeline, December 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top